Provectus Biopharmaceuticals: Short-Term Catalysts and Positive Trial Results Could Help Shares - FOX 18 Quad Cities News and Weather

Provectus Biopharmaceuticals: Short-Term Catalysts and Positive Trial Results Could Help Shares

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Small Cap Specialists, LLC

NEW YORK, May 13, 2014 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) is a development stage biopharmaceutical company that is primarily engaged in developing oncology and dermatology therapies through its two predominant drug candidates, PV-10 and PH-10. The company is working to develop PV-10 for the treatment of several life-threatening cancers, including metastatic melanoma, liver cancer (also known as Hepatocellular carcinoma, or HCC), and breast cancer. Meanwhile, their other drug candidate, PH-10, is being developed to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis (a type of eczema). Aside from the company's leading drug candidates, PVCT also holds patents and other intellectual property that may be used in over-the-counter (OTC) products. Some of these OTC products include GloveAid, Pure-ific, Pure-Stick, and Pure N Clear.

Primary liver cancer (HCC) is the fifth leading cause of death related to cancer in the world in men and seventh in women, with the world market for liver cancer drugs projected to exceed $2 billion by 2015. Meanwhile, GlobalData estimates the melanoma therapeutics market will grow to $1.4 billion by 2017 (a CAGR of almost 17% each year), while the global market for breast cancer drugs should reach over $11 billion by 2016.

Compared to the global cancer market, the dermatology market is also very large in size, especially with regards to psoriasis. In fact, the National Psoriasis Foundation reports that approximately 125 million people worldwide have psoriasis, while GBI Research recently estimated that the global psoriasis market will grow from about $5 billion in 2013 to $10.4 billion in 2020. Additionally, GlobalData estimates the global eczema therapeutics market will double in size from over $2 billion in 2010 to almost $4 billion in 2018, representing a CAGR of over 8%.

A full in-depth analyst report on PVCT that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/PVCT-CFA-Report

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER    

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

COMPLIANCE PROCEDURE   

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Maggi, CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

A full disclaimer can be found by viewing the full analyst report.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Contact: admin@smallcapir.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow